Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NRX Pharmaceuticals, Inc. - Common Stock (NQ:NRXP)

2.260 UNCHANGED
Streaming Delayed Price Updated: 4:15 PM EDT, Apr 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NRX Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
News headline image
$300 Million in Milestones Plus Tiered Double-Digit Royalties from Accepted Terms to License and Distribute NRX-100 Drug: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
Via Get News
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Earnings Scheduled For March 17, 2025 ↗
 
Via Benzinga
News headline image
HOPE Therapeutics Secures Financing For Ketamine Clinic Expansion ↗
HOPE Therapeutics, Inc., a subsidiary of NRx Pharmaceuticals, Inc. (NASDAQ: NRXP), 
Via Benzinga
News headline image
Small-Cap NRx Pharma’s Stock Draws Heavy Retail Buzz After Securing $27M Funding ↗
Chairman Jonathan Javitt said the resources committed are expected to bring NRx to the $100 million revenue threshold. 
Via Stocktwits
News headline image
What's Going On With NRX Pharmaceuticals Stock Tuesday? ↗
NRX Pharmaceuticals shares are moving higher on Tuesday after it invested $27 million in its subsidiary HOPE Therapeutics. 
Via Benzinga
News headline image
Agreement for $27 Million in Funding for Expanding Clinic Acquisitions and Operations, Plus New Drug Application for Treatment of Suicidal Depression: NRx Pharmaceuticals, Inc. Stock Symbol: NRXP
Via Get News
News headline image
What's Going On With NRX Pharmaceuticals Stock Thursday? ↗
NRX shares are trading higher on Thursday after the company announced a joint acquisition initiative with Hope Therapeutics to buy Kadima Neuropsychiatry Institute. 
Via Benzinga
News headline image
Why MicroStrategy Shares Are Trading Higher By Over 5%; Here Are 20 Stocks Moving Premarket ↗
Shares of MicroStrategy Incorporated (NASDAQ:MSTR) rose sharply in today's pre-market trading. 
Via Benzinga
News headline image
New Drug Application to the FDA for the Treatment of Suicidal Depression that Affects Over 13 Million Americans Each Year: NRx Pharmaceuticals, Inc. (Stock Symbol: NRXP)
Via Get News
Jonathan Javitt, CEO of NRx Pharmaceuticals Inc. (NASDAQ: NRXP), to Present at NobleCon20
Via Investor Brand Network
Plans for New Acquisition of Clinics Generating $100 Million to Complement Progress on Accelerated Drug Approval for Bipolar Depression and Related Disorders: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
Via Get News
Topics Regulatory Compliance
Substantial Funding, Debt Resolution, HOPE Dividend, Successful Clinical Trial Towards Accelerated Drug Approval for Bipolar Depression: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
Via Get News
Topics Regulatory Compliance Retirement
News headline image
Substantial Funding, Debt Resolution, HOPE Dividend, Successful Clinical Trial Towards Accelerated Drug Approval for Bipolar Depression: Nasdaq: NRXP
HOPE Therapeutic Subsidiary Focused on Developing a Best-in-Class Network of Clinics for Patients with Suicidal Depression and Related Disorders. HOPE is Planned to be Spun Out as a Separate Company to... 
Via PRLog
Topics Regulatory Compliance
News headline image
NRXP Stock Earnings: NRX Pharmaceuticals Misses EPS for Q2 2024 ↗
NRXP stock results show that NRX Pharmaceuticals missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Alignment with FDA on Pediatric Study Plan and Accelerated Approval to Treat Bipolar Depression and Akathisia: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
Via Get News
Accelerated Approval to Treat Bipolar Depression and Akathisia Could Yield Over $150 in Revenue Per Share; Planned HOPE Subsidiary Spinoff to Continue: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
Via Get News
NRx Pharmaceuticals Highlights Breakthrough Oral Antidepressant’s Efficacy in Reducing Suicidality in Bipolar Depression at ASCP June 2024 Meeting: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
Via Get News
First Oral Antidepressant Clinically Demonstrated to Reduce Suicidality in Bipolar Depression with Data Supporting Accelerated Approval Process: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
Via Get News
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
NRXP Stock Earnings: NRX Pharmaceuticals Misses EPS for Q1 2024 ↗
NRXP stock results show that NRX Pharmaceuticals missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
NRx Pharmaceuticals Eyes First Commercial Revenue in 2024, Announces Breakthroughs in Bi-Annual Milestone Update
Via ACCESSWIRE
Final Clinical Trial Results Show Superior Safety and Efficacy for NRX-101; Plans to Seek Accelerated Approval for Bipolar Depression and Schizophrenia: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
Via Get News
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
Gold Down Over 2%; 3M Profit Beats Expectations ↗
 
Via Benzinga
News headline image
Why H&E Equipment Services Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Why Is NRx Pharmaceuticals Stock Falling After Data From Suicidal Bipolar Depression Study ↗
NRX Pharmaceuticals announces Phase 2b/3 trial findings of NRX-101 vs. Lurasidone for Suicidal Bipolar Depression. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.